EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study

Chih-Hao Chang iD, Shih-Hao Huang, Hung-Yu Huang, Meng-Hung Lin iD, Chung-Shu Lee iD, Hsin-Fu Lee, Jason Chia-Hsun Hsieh iD, Chun-Yu Cheng

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359231221907 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 18.01.2024. Verfasst von Chih-Hao Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chang Gung Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancers are common worldwide. First-line targeted therapy and chemotherapy are both standard treatments in the current guidelines. With the development of new anticancer therapy, the lifespan of patients with late-stage lung cancer has increased. Cardiovascular events can occur during cancer treatment. This observational study aimed to report the incidence of major adverse cardiovascular events (MACE) after cancer treatment using real-world data.

Objectives

Patients diagnosed with advanced-stage lung cancer between January 2011 and December 2017 were enrolled. Data were collected from the Chang Gung Research Database (CGRD).

Design

Retrospective cohort study.

Methods

Baseline characteristics, clinical stages, pathologies, and outcomes were retrieved from the CGRD.

Results

We identified 4406 patients with advanced lung cancer, of whom 2197 received first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy and 2209 received first-line platinum-based chemotherapy. Most patients in the first-line EGFR-TKI group were never-smokers (74.9%), whereas those in the first-line chemotherapy group were ever-smokers (66.0%). The incidence of MACE was not significantly different between the two groups (12.0% versus 11.9%, p = 0.910). However, the incidence of ischemic stroke was higher in the first-line EGFR-TKI group than in the first-line chemotherapy group (3.9% versus 1.9%, p < 0.001).

Conclusion

MACEs are common in patients with advanced-stage lung cancer during treatment. The incidence of MACE was similar between the first-line EGFR-TKI therapy and first-line chemotherapy groups. Although more patients in the EGFR-TKI group were female and never-smokers, the risk of ischemic stroke was higher in patients who received first-line EGFR-TKI therapy than in those who received first-line chemotherapy.

Schlagwörter

Stichwörter der Autor:innen

EGFR mutationMACENSCLCadenocarcinomastroke

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
  • Department of Thoracic Medicine, Chang Gung Memorial Hospital Linkou Branch, 5, Fuxing Street, Guishan District, Taoyuan City 333, Taiwan.
  • Department of Thoracic Medicine, Chang Gung Memorial Hospital Linkou Branch, Taoyuan City, Taiwan.
  • Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital Chiayi Branch, Chiayi County, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, New Taipei City Municipal Tucheng Hospital, New Taipei City, Taiwan.

ORCID-Profile: Chih-Hao Chang, Meng-Hung Lin, Chung-Shu Lee, Jason Chia-Hsun Hsieh

Förderung

  • Chang Gung Medical Foundation

Zitieren

APA

Chang, C. H., Huang, S. H., Huang, H. Y., Lin, M. H., Lee, C. S., Lee, H. F., Hsieh, J. C., & Cheng, C. Y. (2024). Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359231221907

Vancouver

Chang CH, Huang SH, Huang HY, Lin MH, Lee CS, Lee HF, et al. Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359231221907

BibTeX
@article{Chang2024,
  author = {Chang, Chih-Hao and Huang, Shih-Hao and Huang, Hung-Yu and Lin, Meng-Hung and Lee, Chung-Shu and Lee, Hsin-Fu and Hsieh, Jason Chia-Hsun and Cheng, Chun-Yu},
  title = {Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359231221907}
}
Kostenlos starten →